Ascentage Pharma Group International (AAPG) Payables (2023 - 2025)
Ascentage Pharma Group International posted quarterly Payables of $15.0 million for Q4 2025, up 17.55% year-on-year from $12.8 million in Q4 2024, and down 8.28% on a QoQ basis from $16.4 million in Q2 2025.
Ascentage Pharma Group International (AAPG) has 3 years of Payables data on file, last reported at $15.0 million in Q4 2025.
- For the quarter ending Q4 2025, Payables rose 17.55% year-over-year to $15.0 million; the trailing twelve-month figure through Dec 2025 stood at $15.0 million (up 17.55% YoY), and the FY2025 full-year result was $14.9 million, up 16.01% from the prior year.
- Payables for Q4 2025 stood at $15.0 million, down from $16.4 million in the prior quarter.
- Across five years, Payables topped out at $16.4 million in Q2 2025 and bottomed at $10.1 million in Q4 2023.
- The 3-year median for Payables is $13.9 million (2024), against an average of $13.6 million.
- The widest annual swing landed in 2024, when Payables advanced 27.25%; it then increased 17.55% in 2025.
- A 3-year view of Payables shows it stood at $10.1 million in 2023, then rose by 27.25% to $12.8 million in 2024, then increased by 17.55% to $15.0 million in 2025.
- The last three Payables figures came in at $15.0 million (Q4 2025), $16.4 million (Q2 2025), and $12.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.03 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Ascentage Pharma Group International | 1.11 Bn | 937.28 Mn | - | 15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.05 Mn |
| Jun 30, 2025 | 16.41 Mn |
| Dec 31, 2024 | 12.80 Mn |
| Dec 31, 2023 | 10.06 Mn |